Ignite Creation Date:
2025-12-25 @ 2:16 AM
Ignite Modification Date:
2026-03-05 @ 8:13 PM
Study NCT ID:
NCT05863260
Status:
UNKNOWN
Last Update Posted:
2023-05-18
First Post:
2023-05-09
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Tislelizumab Combing Chemoradiotherapy in Recurrent Cervical Cancer
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D002583', 'term': 'Uterine Cervical Neoplasms'}], 'ancestors': [{'id': 'D014594', 'term': 'Uterine Neoplasms'}, {'id': 'D005833', 'term': 'Genital Neoplasms, Female'}, {'id': 'D014565', 'term': 'Urogenital Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D002577', 'term': 'Uterine Cervical Diseases'}, {'id': 'D014591', 'term': 'Uterine Diseases'}, {'id': 'D005831', 'term': 'Genital Diseases, Female'}, {'id': 'D052776', 'term': 'Female Urogenital Diseases'}, {'id': 'D005261', 'term': 'Female Urogenital Diseases and Pregnancy Complications'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D000091662', 'term': 'Genital Diseases'}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'COHORT'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 60}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'startDateStruct': {'date': '2020-11-09', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2023-05', 'completionDateStruct': {'date': '2024-12-31', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2023-05-09', 'studyFirstSubmitDate': '2023-05-09', 'studyFirstSubmitQcDate': '2023-05-09', 'lastUpdatePostDateStruct': {'date': '2023-05-18', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2023-05-18', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-12-31', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'ORR', 'timeFrame': '1 year', 'description': 'Objective response rate'}], 'secondaryOutcomes': [{'measure': '1-year PFS', 'timeFrame': '1 year', 'description': '1-year PFS'}, {'measure': '1-year OS', 'timeFrame': '1 year', 'description': '1-year OS'}]}, 'oversightModule': {'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Cervical Cancer', 'Immune Checkpoint Inhibitor', 'Chemoradiotherapy']}, 'descriptionModule': {'briefSummary': 'Tislelizumab combined with chemoradiotherapy in the treatment of recurrent/ metastasis cervical cancer: a single arm,single center， phase ii and observational clinical study', 'detailedDescription': 'Tislelizumab combined with chemoradiotherapy in the treatment of recurrent/ metastasis cervical cancer: a single arm,single center， phase ii and observational clinical study'}, 'eligibilityModule': {'sex': 'FEMALE', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '70 Years', 'minimumAge': '18 Years', 'genderBased': True, 'samplingMethod': 'PROBABILITY_SAMPLE', 'studyPopulation': 'Patients with recurrent or metastatic cervical cancer after initial standard treatment (including radical surgery or radical radiotherapy), the lesions are located out of the field of previous radiotherapy, with no more than 5 recurrent or metastatic foci, and the radiotherapy is feasible according to the evaluation of radiotherapy physician; and at least 1 lesion (without previous radiotherapy) meets the target lesion standard of RECIST 1.1', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. For patients with recurrent or metastatic cervical cancer after initial standard treatment (including radical surgery or radical radiotherapy), the lesions are located out of the field of previous radiotherapy, with no more than 5 recurrent or metastatic foci, and the radiotherapy is feasible according to the evaluation of radiotherapy physician; and at least 1 lesion (without previous radiotherapy) meets the target lesion standard of RECIST 1.1;\n2. Cervical adenocarcinoma, squamous cell carcinoma or adenosquamous cell carcinoma confirmed by previous histology;\n3. Surgical resection is not recommended for recurrent lesions, or patients choose not to accept surgery voluntarily;\n4. The researchers evaluated the suitability of radiotherapy\n5. ECoG 0-1; life expectancy \\> 6 months;\n6. Aged 18-70 years;\n7. No serious allergic history;\n8. Hemoglobin \\> 100 g / L, WBC \\> 3.5 \\* 10 \\^ 9 / L, neutrophils \\> 1.5 \\* 10 \\^ 9 / L, platelets \\> 100 \\* 10 \\^ 9 / L, Cr \\< 1.5 \\* normal upper limit, TB \\< 2.5 \\* normal upper limit, AST and Al \\< 2.5 \\* normal upper limit, AKP \\< 2.5 \\* normal upper limit;\n9. Ability to sign informed consent.\n\nExclusion Criteria:\n\n1. Histologically, small cell (neuroendocrine) cervical cancer, mucinous adenocarcinoma, carcinosarcoma and other pathological types were confirmed;\n2. Primary malignant tumor with activity in other parts, except for the following:\n\n Those who have been cured have no known active disease at least 5 years before the first IP administration, and the potential risk of recurrence is low;\n\n Fully treat non melanoma skin cancer or malignant nevus without disease signs;\n\n Fully treated carcinoma in situ, no signs of disease.\n3. The recurrent lesions have received chemotherapy, radiotherapy or other anti-tumor treatment;\n4. Bone metastasis;\n5. Brain metastasis;\n6. Pregnant or lactating patients;\n7. In the past, there was abnormal thyroid function, and under the condition of drug treatment, thyroid function could not be maintained in the normal range;\n8. Diagnosis of immune deficiency or treatment with chronic systemic steroids (doses more than 10 mg per day of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days before enrollment;\n9. Patients with active autoimmune diseases need systemic treatment in the past 2 years;\n10. A history of (noninfectious) pneumonia requiring steroids or current pneumonia;\n11. There are active infections that need systematic treatment;\n12. Known history of human immunodeficiency virus (HIV) infection;\n13. Known history of hepatitis B or known active hepatitis C virus infection;\n14. Known history of active tuberculosis (TB);\n15. Uncontrolled comorbidities, including but not limited to: persistent or active infection, symptomatic congestive heart failure, uncontrolled hypertension, uncontrolled diabetes, uncontrolled arrhythmias, active interstitial lung disease (ILD), severe chronic gastrointestinal disease with diarrhea, or may limit compliance with study requirements, leading to AE Mental / social problems that significantly increase or affect the ability of subjects to provide written informed consent;\n16. 14 days before admission, the operation was too large and had not recovered;\n17. Participate in other clinical trials at present or within 28 days before selection;\n18. Any indications, including but not limited to other anti-CTLA-4, anti-PD-1, anti-PD-L1 and anti-PD-L2 antibodies or therapeutic anti-cancer vaccines, were treated by immunomediated therapy prior to the study;\n19. Any synchronous chemotherapy, research drug, biological product, or hormone therapy used to treat tumors. Hormone therapy can also be used to treat non tumor related diseases (e.g., hormone replacement therapy);\n20. Allogeneic tissue / solid organ transplantation was carried out.'}, 'identificationModule': {'nctId': 'NCT05863260', 'briefTitle': 'Tislelizumab Combing Chemoradiotherapy in Recurrent Cervical Cancer', 'organization': {'class': 'OTHER', 'fullName': 'Fudan University'}, 'officialTitle': 'Tislelizumab (Anti-PD-1) Combined With Definitive Chemoradiotherapy in Recurrent Cervical Cancer (PILOT-2020-511): a Single-arm, Phase 2 Trial', 'orgStudyIdInfo': {'id': 'PILOT-2020-511'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Intervention', 'description': 'Paclitaxel 135mg / m2d1 + cisplatin 60mg / m2d1 (cisplatin resistance or cisplatin intolerance changed to carboplatin AUC = 5d1), q3w × 4 and Standard IMRT and radiotherapyTislelizumab 200mg, IV, q3w, the day before radiotherapy', 'interventionNames': ['Drug: Treatment Group']}], 'interventions': [{'name': 'Treatment Group', 'type': 'DRUG', 'description': 'Treatment Group', 'armGroupLabels': ['Intervention']}]}, 'contactsLocationsModule': {'locations': [{'zip': '200032', 'city': 'Shanghai', 'state': 'Shanghai Municipality', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'JUN ZHU, M.D.', 'role': 'CONTACT', 'email': 'dragonzld@163.com', 'phone': '8613564972482'}], 'facility': 'Fudan University Shanghai Cancer Center', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Fudan University', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Professor', 'investigatorFullName': 'Jun Zhu', 'investigatorAffiliation': 'Fudan University'}}}}